1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

  • August 2017
  • 254 pages
  • GBI Research
Report ID: 5043172

Summary

Table of Contents

Search Inside

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

Summary
Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, withsymptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 61 products in development for this indication, by 40 companies and five academic institutions. Key companies operating in this pipeline space include NLS Pharma Group and Shire.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. There are a total of 191 products in development for this indication, by 112 companies and 20 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Sumitomo Dainippon Pharma, Luye Pharma Group, Otsuka Holdings and Vanderbilt University.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. There are a total of 134 products in development for this indication, by 85 companies and nine academic institutions. Key companies operating in this pipeline space include Omeros Corp, Suven Life Sciences, Heptares Therapeutics, Merck & Co, Sumitomo Dainippon Pharma and Vanderbilt University.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. There are a total of 11 products in development for this indication, by nine companies and one academic institution. Key companies operating in this pipeline space include Catalyst Pharmaceuticals, who are fielding two pipeline products.

Across all four of these indications, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

The report " Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017", provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Scope
- Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Diabetic Neuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • $ 5795
  • Industry report
  • June 2017
  • by Transparency Market Research

Global Diabetic Neuropathy Market: Overview The report on diabetic neuropathy market analyzes the current and future scenario of the global market. Increase in prevalence of diabetic neuropathy, advent ...

Diabetic Neuropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • $ 5795
  • Industry report
  • June 2017
  • by Transparency Market Research

Global Diabetic Neuropathy Market: Overview The report on diabetic neuropathy market analyzes the current and future scenario of the global market. Increase in prevalence of diabetic neuropathy, advent ...

Fabry Disease - Market Insights, Epidemiology and Market Forecast – 2025

  • $ 5750
  • Industry report
  • September 2017
  • by Delve Insight

DelveInsight’s “Fabry Disease - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Fabry Disease for the 7MM (United ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.